Back

Cardioprotection by soluble urokinase plasminogen activator receptor (suPAR) in an in vivo model of myocardial infarction with ischaemia-reperfusion

30 August 2026 (17:15 - 17:45)
Organised by: Logo
Congress Presentation Part of: Ischaemia-reperfusion injury: new biological mechanisms of repair Reperfusion and Reperfusion Injury ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Janice Chew-Harris

University of Otago Christchurch, Christchurch (New Zealand)

4 More presentations in this session

Presentation thumbnail
Increased interleukin-6 levels associate with worse 1-year outcome after acute myocardial infarction and link infarct size, impaired iron status and heart failure
Doctor M. Matter (Zurich, CH)
Abstract Slides Video
Presentation thumbnail
Axl improves cardiac microvascular injury via mitochondrial Ca2+ and Fe2+ homeostasis in cardiac ischemia-reperfusion injury
Doctor Y. Li (Shanghai, CN)
Abstract Slides Video
Presentation thumbnail
LRP3 promotes angiogenesis after ischemia and affects the survival and prognosis of patients with myocardial infarction.
Doctor C. Zhai (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Fat attenuation index and plaque characteristics on coronary computed tomography angiography correlation with high-risk plaques identified by optical coherence tomography
Doctor L. Guo (Dalian, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Ischaemia-reperfusion injury: new biological mechanisms of repair

The Event

Event poster

ESC Congress 2026

30 August 2026 17:15 CET
You may be interested in
thumbnail
Congress Presentation
The cardioprotective potential of soluble urokinase Plasminogen Activator Receptor (suPAR) in myocardial ischemia.
1 September 2024
thumbnail
Congress Presentation
The role of macrophage migration inhibitory factor in predicting left ventricular remodeling in patients with acute myocardial infarction
21 May 2022
thumbnail
Congress Presentation
Does IL-6 receptor blockage following out-of-hospital cardiac arrest have protective effects on the endothelium? - A substudy of the IMICA trial
14 March 2025
thumbnail
Congress Presentation
Intravenous administration of IV-STATIN CARDIOSHIELD during myocardial infarction renders higher cardioprotection than oral atorvastatin given shortly after reperfusion: a translational CMR study
1 September 2019

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources